Companies: 10,795·Total market cap: $144.5T
NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGMNASDAQHealthcare
$1.54
$-0.02(-1.28%)
Market Cap$128532096
P/E Ratio
52W High$4.69
52W Low$0.6002
Overview

NGM Biopharmaceuticals, Inc. (NGM) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · NGM · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.69ngm eps ttm · ngm earnings per shareEarnings history
PE Ratio (TTM)ngm pe ratio ttm · ngm price to earningsPE Ratio deep dive
Revenue (TTM)$4.4Mngm revenue ttm · ngm annual revenueFull revenue history
Dividend YieldNo Dividenddoes ngm pay dividends · ngm dividend yieldDividend history
Shares Outstanding82.5Mngm shares outstanding · ngm floatShares outstanding history
Next EarningsTBAngm earnings date · ngm next earningsEarnings history

Financial Snapshot

Full Financials
FY 2023Revenue$4.4M▼ 92.02% YoY
202120222023
ngm biopharmaceuticals, inc. revenue · ngm revenue 2023
FY 2023Net Income-$142.4M▲ +10.50% YoY
202120222023
ngm biopharmaceuticals, inc. net income · ngm profit 2023
FY 2023EPS$-1.73▲ +13.07% YoY
202120222023
ngm eps · ngm biopharmaceuticals, inc. earnings per share 2023
TTM:Revenue: $4.4MNet Income: -$139.8MEPS: $-1.69View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy15 analystsis ngm a buy · ngm analyst rating
Strong Buy
0
Buy
10
Hold
5
Sell
0
Strong Sell
0
12-Month Price Target
$4.00Low
$1.54Current
$16.50Avg Target971.43% upside
$29.00High
ngm price target · ngm 12 month forecast

Total: 15 · Buy rate: 66.7%

The NGM analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $16.50, representing +971.43% upside from the current price of $1.54.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+6.94%
YTD+23.20%
1Y-60.91%
5Y-89.65%

About NGM Biopharmaceuticals, Inc.

CEODavid J. Woodhouse
IPO DateApr 4, 2019
Employees138
CountryUS
Websitengmbio.com

NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. Th…

what is ngm biopharmaceuticals, inc. · ngm stock overview · ngm biopharmaceuticals, inc. company profile · who is ngm biopharmaceuticals, inc. ceo · ngm NASDAQ · ngm biopharmaceuticals, inc. headquarters · ngm biopharmaceuticals, inc. business segments

About Stock Overview & Key Data

NGM Biopharmaceuticals, Inc. (NGM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 4, 2019. As of the latest trading session, NGM stock price is $1.54, with a market capitalization of $128.5M. The stock has returned -60.91% over the past 12 months and +23.20% year-to-date.

According to 15 Wall Street analysts, the consensus rating for NGM Biopharmaceuticals, Inc. stock is Buy, with an average 12-month price target of $16.50. In fiscal year 2023, NGM Biopharmaceuticals, Inc. reported revenue of $4.4M and net income of -$142.4M. For detailed data — including NGM Biopharmaceuticals, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, NGM Biopharmaceuticals, Inc. (NGM) stock price is $1.54. The stock is traded on NASDAQ under the ticker symbol NGM. The 52-week range is $0.60 – $4.69.

NGM stock priceNGM quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice